Syed Shafi Asghar, Ph.D.

Division of Biochemistry and Immunology, Department of Dermatology, Academisch Medisch Centrum, University of Amsterdam, Amsterdam, The Netherlands

Received 12/08/95; Accepted 26/01/96; On-line 03/01/96

1. S.S. Asghar: Pharmacological manipulation of the complement system. Pharm Rev 36, 223-44 (1984)

2. S.S. Asghar: Pharmacological manipulation of complement in dermatology. In: Skin Immune System (ed. J.D. Bos). 2nd edition. CRC Press, Inc. Boca Raton, Florida. 1996; in press.

3. M.K. Liszewiski & J.P. Atkinson. The complement system. In: Fundamental Immunology (ed. W.A. Paul). Raven press. New York. 1993; 917-39

4. S.S. Asghar: Complement in physiopathology of skin. In: Skin Immune system (ed. J.D.Bos). CRC Press, Inc. Boca Raton, Florida. 1990; 207-41

5. H.J. Muller-Eberhard: Molecular organization and function of the complement system. Ann Rev Biochem 57, 321-47 (1988)

6. S.S. Asghar: Complement and complement regulatory proteins. In: Skin Immune system (ed. J.D.Bos). CRC Press, Inc. Boca Raton, Florida. 1996; in press.

7. S.S. Asghar: Membrane regulators of complement activation and their aberrant expression in disease. Lab Invest 72, 254-71 (1995)

8. B.P. Morgan & S. Meri: Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 15, 369-96 (1994)

9. D. Hourcade, V.M. Holers, J.P. Atkinson: The regulators of complement activation (RCA) gene cluster. Adv Immunol 45, 381-416 (1989)

10. Z.N. Oltvai, E.C.C. Wong, J.P. Atkinson, K.S.K. Tung: C1-inhibitor deficiency: Molecular and Immunological basis of hereditary and acquired angioedema. Lab Invest 65, 381-8 (1991)

11. A.E. Davis III: C1 Inhibitor and hereditary angioneurotic edema. Ann Rev Immunol 6, 595-628 (1988)

12. M. Hessing: The interaction between complement C4b-binding protein and the vitamin K dependent protein S forms a link between blood coagulation and complement system. Biochem J 227, 581-92 (1991)

13. R.D. Campbell, S.K.A. Law, K.B.M. Reid, R.B. Sim: Structure, organization and regulation of the complement genes. Ann Rev Immunol 6, 161-95 (1988)

14. R.B. Sim, K. Colbe, M.A. Mc Aleer, O. Doninguez & V.M. Dee: Genetics and deficiencies of soluble regulatory proteins of the complement system. Int Rev Immunol 10, 65-86 (1993)

15. P.F. Zipfel & C. Skerka: Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunology Today 15, 121-6 (1994)

16. D.E. Jenne & J. Tschopp: Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 17, 154-9 (1992)

17. K.T. Preissner: Structure and biological role of vitronectin. Ann Rev Cell Biol 7, 275-310 (1991)

18. D.M. Lubin & J.P. Atkinson: Decay-accelerating factor: Biochemistry, molecular biology, and function. Ann Rev Immunol 7, 35-58 (1989)

19. A. Nicolson-Weller: Decay accelerating factor (CD55). Curr Top Microbiol Immunol 178, 7-30 (1992)

20. M.K. Liszewski, T.W. Post & J.P. Atkinson: Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Ann Rev Immunol 9, 431-55 (1991)

21. J.M. Ahearn & D.T. Fearon: Structure and function of the complement receptor CR1 (CD35) and CR2 (CD21). Adv Immunol 46, 183-219 (1989)

22. W.W. Wong: Structural and functional correlation of the human complement receptor type 1. J Invest Dermatol 94 (suppl), 64-67 S (1990)

23. G.T. Venneker & S.S. Asghar: CD59: A molecule involved in antigen presentation as well as down regulation of membrane attack complex. Exp Clin Immunogen 9, 33-47 (1992)

24. L.A. Walsh, M. Tone, S. Thiru, H. Waldmann: CD59 antigen - a multifunctional molecule. Tissue antigens 40, 213-220 (1992)

25. A. Davies & P.J. Lachman: Membrane defense against complement lysis: The structure and biological properties of CD59. Immunol Res 12, 258-75 (1993)

26. L.S. Zalman: Homologous restriction factor. Curr Topics Microbiol Immunol 178, 87-99 (1992)

27. A.J. Tenner & M.M Frank: Activator bound C1 is less susceptible to inactivation by C1 inhibitor than is fluid phase C1. J Immunol 137: 625-30 (1986)

28. A. Leimgruber, W.A. Jaques & P.J. Spaeth: Hereditary angioedema- Uncomplicated Maxillofacial surgery using short term C1-inhibitor replacement therapy. Int Arch Allergy Immunol 101, 107-12 (1993)

29. J. Gadek, S.W. Hosea, J.A. Gelfand & M.M. Frank: Response of variant hereditary angioneurotic edema phenotypes to danazol therapy. Genetic implications. J Clin Invest 64, 280-6 (1979)

30. R. Guerrero, F. Velasco, M. Rodriguez, A. Lopez, R. Rojas, M.A. Alvarez, R. Villalba, V. Rubio, A. Torres & D. del Castillo: Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J. Clin Invest 91, 2754-60 (1993)

31. C.E. Hack, A.C. Ogilia, B. Eisele, P.M. Jansen, J. Wagstaff & L.G Thijs: Initial studies on administration of C1-esterase inhibitor to patients with septic shock or with a vascular leakage syndrome induced by interleukin-2 therapy. Progr Clin Biol Research 388, 335-57 (1994)

32. R.I. Schiff: Intravenous gammaglobulin: pharmacology, clinical uses and mechanism of action. Pediatr Allergy Immunol 5, 63-7 (1994)

33. J.M. Dwyer: Manipulating the immune system with immune globulins. New Engl J Med 326, 107-16 (1992)

34. V.R. De Souza, S.V. Kaveri & M.D. Kazatchkine: Intravenous Immunoglobulin (IVIG) in the treatment of autoimmune and inflammatory diseases. Clin Exp Rheumatol 11 (Suppl), S 33-6 (1993)

35. K.E. Roux & D.L. Tankersley: A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 144, 1387-95 (1990)

36. M.G. Macey & A.C. Newland: CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Hematol 76, 513-20 (1990)

37. I.N. van Schaik, I. Lundkvist, M. Vermeulen & A. Brand: Ployvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 12, 1-10 (1992)

38. D.Engelhard, J.L. Waner, N.Kapoor & R.A.Good: Effect of intravenous immunoglobulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr 108, 77-81 (1986)

39. T. Shimozato, M. Iwata, H. Kawada & N. Tamura: Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 72, 497-501 (1991)

40. J.A. Schifferli, L. Didierjean & J.H. Saurat: Immunomodulatory effects of intravenous immunoglobulin G. J Rheumatol 18, 937-9 (1991)

41. W.P. Arend, M.F. Smith, R.W.Janson & F.G. Joslin: IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol 147,1530-6 (1991)

42. M. Qi & J.A.Schifferli: Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum 38, 146 (1995)

43. M. Basta, L.F. Fries & M.M. Frank: High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77, 376-80 (1991)

44. P. Berchtold P & R. Mc Millen: Intravenous immunoglobulin: new aspects of mechanism of action in chronic ITP. In: Immunotherapy with Intravenous Immunoglobulins (ed. P. Imbach), Academic Press, London. 1991; 245-52

45. J.M. Lusher & I. Warrier: Use of intravenous immunoglobulin in children and adolescents with idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Am J Med 4 (Suppl A), 10-6 (1987)

46. J.P. Bussel. The use of intravenous-g-globulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 53, S 147-55 (1989)

47. S.T. Shulman: Kawasaki disease and IVIG: what is going on here ? In: Immunotherapy with Intravenous Immunoglobulins (ed. P. Imbach). Academic Press, London. 1991; 261-8

48. J.W. Newburger, M. Takahashi, J.C. Burns, A.S. Beiser, K.J. Chung, C.E. Duffy, M.P. Golde, W.H. Mason, V. Reddy, S.P. Sanders, S.T. Shulman, J.W. Wiggins, R.W. Hicks, D.R. Fulton, A.B. Lewis, D.Y.M. Leung, T. Colton, F.S. Rosen & M.E. Malish: The treatment of Kawasaki syndrome with intravenous gamma globulins. New Engl J Med 315, 341-7 (1986)

49. S. Nonoyama: Immunological abnormalities and endothelial cell injury in Kawasaki disease. Acta Pediatr Jpn 33, 752-5 (1991)

50. E.S. Lekora, L. Joffe & M.P. Golde: Antigenic recognition of intravenous gamma globulin of selected bacteria isolated from throats of patients with Kawasaki syndrome. Pediatr Infect Dis J 9, 620-3 (1990)

51. E. Arsura: Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 53, S 170-9 (1989)

52. P. Gajdos: Intravenous immunoglobulin in myasthenia gravis. Clin Exp Immunol 97 (Suppl 1), 49-51 (1994)

53. P.A. van Doorn, M. Vermeulen, A. Brand, P.G.H. Mulder & H.F.M. Busch: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 48,217-220 (1991)

54. C. Coulam, A. Peters, J. Mc Intyre & W. Faulk: The use of IVIG for the treatment of recurrent spontaneous abortion. In: Immunotherapy with intravenous immunoglobulins (ed. P. Imbach). Academic Press, London, 1991, 395-400

55. O. Heine and G. Mueller-Eckhardt: Intravenous immune globulin in recurrent abortion. Clin Exp Immunol 97 (Suppl 1), 39-42 (1994)

56. A.K. Gupta, N.H. Shear & D.N. Sauder: Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 32, 140-2 (1995)

57. C. Mohr, C. Sunderkotter, A. Hilderbrand, K. Biel, A. Rutter, G.H. Rutter, T.A. Leuger & G. Kolde: Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 132, 824-6 (1885)

58. A.K. Sharma & M.K. Pangburn: Biologically active recombinant factor H: synthesis and secretion by baculovirus system. Gene 143, 301-2 (1994)

59. R.G. Trapp, M. Fletcher, J. Forristall & C.D. West: C4 binding protein deficiency in a patient with atypical Behcet's disease. J Rheumatol 14, 135-8 (1987)

60. A.J. Bonnin, H.J. Zeitz & A. Gewurz: Complement factor I deficiency with recurrent aseptic meningitis. Arch Intern Med 153, 1380-3 (1993)

61. J.B. Ziegler, C.A. Alper, R.S. Rosen, P.J. Lachmann & L. Sherington: Restoration by purified C3b inactivator of complement mediated function in vivo in a patient with C3b inactivator deficiency. J Clin Invest 55: 668-72 (1975)

62. M.E. Medof, E.I. Walter, J.L. Rutgers, D.M. Knowles & V. Nussenzeweig V: Identification of the complement decay accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165, 848-64 (1987)

63. T. Hara, S. Kuriyama, H. Kiyohara, M. Nagase, M. Matsumoto & T. Saya: Soluble forms of membrane cofactor protein (CD 46, MCP) are present in plasma, tears and seminal fluid in normal subjects. Clin Exp Immunol 89: 490-4 (1992)

64. S. Yoon & D.T. Fearon: Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol 134, 3332-8 (1985)

65. P. Moran, H. Beasley, A. Gorrell, E. Martin, P. Gribling, H. Fuchs, N. Gillet, L.E. Burton & I.W. Caras: Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 149, 1736-43 (1992)

66. D.M. Lubin & K.E Coyne: Phospholipid anchored and transmembrane versions of either decay- accelerating factor or membrane cofactor protein show equal efficiency in protection from complement mediated cell damage. J Exp Med 174, 35-44 (1991)

67. G.C. Yeh, H.C. Marsh Jr, G.R. Carson, L. Berman, M.F. Concino, S.M. Scesney, R.E. Kuestner, R. Skibbens, K.A. Donahue & S.H. Ip: Recombinant soluble human complement receptor type 1 inhibits inflammation in the reverse passive Arthus reaction in rats. J Immunol 146, 250-6 (1991)

68. K.R. Kalli, P. Hsu & D.T. Fearon: Therapeutic uses of recombinant complement proteins. Springer Semin Immunopathol 15, 417-31 (1994)

69. J.L. Platt: A perspective on xenograft rejection and accommodation. Immunol Rev 141, 127-49 (1994). 70. W.M. Baldwin 3rd, S.K. Pruit, R.B. Brauer, M.R. Daha & F. Sanfilippo: Complement in organ transplantation. Transplantation 59, 797-808 (1995)

71. A.P. Dalmasso: The complement system in xenotransplantation. Immunopharmacology 24, 149-60 (1992)

72. D.H. Sachs: The pig as a potential xenograft donor. Veterin Immunol Immunopathol 43, 185-91 (1994)

73. E. Cozzi, G.A. Langford, L. Wright, A. Tucker, M. Yannoutsos, A. Richards, A. Rosengards, K. Elsome, R. Lancaster & D.J.G. White: Comparative analysis of human DAF expression in the tissues of transgenic pigs and man. Transpl Proceed 27, 319-20 (1995)

74. G. Rosengard, N. Cary, J. Horseley, C. Belcher, G. Lagford, E. Cozzi, J. Wallwork, D.J.G. White: Endothelial expression of human decay accelerating factor in transgenic pig tissue. A potential approach for human complement inactivation in discordant xenografts. Transpl Proc 27, 326-27 (1995)

75. F.D. Moore Jr: Therapeutic regulation of the complement system in acute injury states. Adv Immunol 56, 267-99 (1994)

76. H.J. Weisman, T. Bartow, M.K. Leppo, H.C. Marsh Jr, G,R. Carson, M.F. Concino, M.P. Boyle, K.H. Roux, M.L. Wiesfeldt & D.T. Fearon: Soluble human complement receptor type 1 : in vivo inhibitor of complement suppresses post-ischemic myocardial inflammation and necrosis. Science 249, 146-51 (1990)

77. J. Hill, T.H. Lindsay, F. Ortiz, C.G. Yeh, H.B. Hechtman, F.D. Moore Jr: Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol 149, 1723-8 (1992)

78. M. Pemberton, G. Anderson, V. Vetvicka, D.E. Justus & G.D. Ross. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia and reperfusion injury of skeletal muscle. J Immunol 150, 5104-13 (1993)

79. T. Morisaki, T. Goya, H. Toh, K. Nishihara & Toisu M: The anti-Mac-1 monoclonal antibody inhibits neutrophil sequestration in lung and liver in a septic murine model. Clin Immunol Immunopathol 61, 365-75 (1991)

80. P. Grob, M. Holch, W. Fierz, W. Glinz & S. Geroulanos: Immunodeficiency after major trauma and selective surgery. Pediatr Infect Dis J 7, S37-42 (1988)

81. M.S. Mulligan, C.G. Yeh, A.R. Rudolph & P.A. Ward: Protective effects of soluble CR1 in complement and neutrophil-mediated injury. J Immunol 148, 1479-85 (1992)

82. S.K. Pruitt, A.D. Kirk, R.R. Bollinger, H.C. Marsh, B.H. Collins, J.L. Levin, J.R. Mault, J.S. Heinle, S. Ibrahim, A.R. Rudolph, W.M. Baldwin & F. Sanfilippo: The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57, 363-70 (1994)

83. S.K. Pruitt & R.R. Bollinger: The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 50, 350-5 (1991)

84. W. Xia, D.T. Fearon, F.D. Moore Jr, F.J. Schoen, F. Ortiz & RL Kirkman: Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Trans Proc 24: 479-80 (1992)

85. B.P. Morgan: Complement regulatory molecules: application to therapy and transplantation. Immunology Today 16, 257-9 (1995)

86. U.S. Ryan: Blockade of complement using soluble complement receptors. Cambridge Healthcare Institute's Conference on Prevention of Reperfusion Injury. Omni Royal Orleans, New Orleans, Louisiana, USA. February 20-21, (1995)

87. W.L. Fodor, B.L. Williams, L.A. Matis, J.A. Madri, S.A. Rollins, J.W. Knight, W. Velander & S.P. Squinto: Expression of functional complement inhibitor in a transgenic pig as a model for prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sciences USA. 91, 11153-7 (1994)